SINTX Technologies Inc Dossier - Source-backed chat

SINTX Technologies Inc

SINTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.75

Intrinsic Value $1.95median of 2 methodsbased on filings through 31 Mar 2026

Market Price $2.13Price as of 1 Oct 2026

Near fair valueIntrinsic value is 9% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $14.2M

Enterprise Value $15.6M

Shares Outstanding 6.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SINTX Technologies is transitioning from a materials science research platform into a commercial-stage orthopedic and biomaterials company. The successful first-in-human surgery utilizing its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System in March 2026 marks a critical commercial milestone. While the company faces severe near-term liquidity constraints and a Nasdaq non-compliance notice regarding stockholders' equity, its recent $5.0 million capital raise in June 2026 provides a vital runway to execute its commercialization strategy. Wall Street analysts maintain a highly favorable outlook on the disruptive potential of its silicon nitride platform.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$9.13

High · most bullish analyst$12.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2520%

The company fails to regain Nasdaq compliance and is delisted to the OTC markets. Commercial adoption of the SINAPTIC system stalls, and high cash burn necessitates further highly dilutive equity offerings, depressing the stock price.

Base CaseCentral scenario

$10.0055%

SINTX successfully submits its Nasdaq compliance plan and receives an extension. The $5.0 million capital raise stabilizes the balance sheet in the medium term while product revenues from the foot and ankle segment gradually scale, aligning with H.C. Wainwright's reiterated target.

Bull CaseUpside scenario

$12.0025%

Rapid surgeon adoption of the SINAPTIC Foot & Ankle system and successful OEM licensing of the SiNERGY platform drive exponential revenue growth, quickly resolving going-concern doubts and restoring Nasdaq compliance without further dilutive financing.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary silicon nitride technology platform with proven osteoconductive, pro-osteogenic, and bacteriostatic properties.
Successful entry into the multi-billion-dollar foot and ankle reconstruction market with FDA-cleared SINAPTIC system.
Strengthened near-term balance sheet following a $5.0 million capital raise in June 2026.

Key Investment Risks

Going-concern warning due to historical operating losses and high cash burn rate.
Nasdaq non-compliance risk as stockholders' equity of $904,000 as of March 31, 2026, is below the $2.5 million minimum.
Intense competition from well-funded, established orthopedic device manufacturers.

Thesis Invalidation Triggers

Failure to obtain a Nasdaq compliance extension by July 6, 2026, leading to delisting procedures.
Flat or declining product revenues in Q2 and Q3 2026, indicating poor commercial traction of the SINAPTIC system.
Inability to secure additional strategic partnerships or OEM licensing agreements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.